A study Bavituximab and Pembrolizumab for progressive recurrent/metastatic squamous cell carcinoma of the head and neck

Trial Profile

A study Bavituximab and Pembrolizumab for progressive recurrent/metastatic squamous cell carcinoma of the head and neck

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Bavituximab (Primary) ; Pembrolizumab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 According to a Peregrine Pharmaceuticals media release, National Comprehensive Cancer Network(NCCN) is responsible for oversight and monitoring of this and other two clinical studies (CTP700276383 and CTP700276381) through the research grant.
    • 07 Sep 2017 According to a National Comprehensive Cancer Network media release, Ranee Mehra from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins has received funding through a grant from Peregrine Pharmaceuticals.
    • 14 Jul 2017 According to a Peregrine Pharmaceuticals media release, this trial is expected to be initiated by the end of the calendar year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top